Compare Cassava Sciences Inc (FLNA) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Gold Fields Limited — how do they compare? Cassava Sciences Inc trades at $0.81 (market cap $39.40M), while Gold Fields Limited trades at $37.28 (market cap $31.87B). The key difference: Gold Fields Limited is far larger — about 808.9× Cassava Sciences Inc's market cap, and Gold Fields Limited pays a 6% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Gold Fields Limited for 49 Days on average.
| FLNA | GFI | |
|---|---|---|
Market Cap | $39.40M | $31.87B |
Volume | 759,018 | 4,169,651 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $61.52 |
52-Week Low | $0.68 | $31.25 |
Typical Hold Time | 37 Days | 49 Days |
Enterprise Value | -$43.28M | $32.47B |
Dividend Yield | — | 6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Gold Fields (GFI) trades at $35.05, down 3.1% amid market reaction to its rejected $27 billion bid for Northern Star. The stock shows a bearish technical signal with key support at $34-$35, while fundamentals remain strong with a 40.76% net margin and low P/E of 7.3. Recent earnings saw mixed results, with one beat and three misses against expectations.
The outlook is balanced: robust cash flow and high profitability support upside toward the $52.75 analyst target, but acquisition uncertainty and technical weakness pose near-term risks. Investor sentiment is cautious pending clarity on M&A strategy and capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
